Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Entire DC Network
The “Rights” Of Precision Drug Development For Alzheimer’S Disease, Jeffrey Cummings, Howard H. Feldman, Philip Scheltens
The “Rights” Of Precision Drug Development For Alzheimer’S Disease, Jeffrey Cummings, Howard H. Feldman, Philip Scheltens
School of Medicine Faculty Publications
There is a high rate of failure in Alzheimer’s disease (AD) drug development with 99% of trials showing no drug-placebo difference. This low rate of success delays new treatments for patients and discourages investment in AD drug development. Studies across drug development programs in multiple disorders have identified important strategies for decreasing the risk and increasing the likelihood of success in drug development programs. These experiences provide guidance for the optimization of AD drug development. The “rights” of AD drug development include the right target, right drug, right biomarker, right participant, and right trial. The right target identifies the appropriate …